If you are able to provide cardioprotection, then you will have anti-cancer synergy. The mechanisms of cardioprotection require greater concentrations of Bisantrene than anti-cancer. 79% of Oncolines cell lines at 500 nM, while meaningful cardioprotection at 1uM across a wide range of drugs. The difference between cardioprotection and synergy is that while some patients should benefit from the anti-cancer synergy, there should be significantly more that are protected from dox cardiotoxicity. Cancerous tissue is more dynamic and less predictable than non-canceroue tissues.
There are many ways to evaluate the combination efficacy in comparison to single agent Dox.
- Forums
- ASX - By Stock
- Ann: Race Appoints George Clinical for Phase 1 Trial of RC220
If you are able to provide cardioprotection, then you will have...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.55 |
Change
-0.020(1.27%) |
Mkt cap ! $264.0M |
Open | High | Low | Value | Volume |
$1.59 | $1.62 | $1.51 | $218.3K | 138.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 95 | $1.53 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.55 | 157 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 29100 | 1.500 |
1 | 353 | 1.470 |
2 | 3444 | 1.440 |
3 | 101000 | 1.420 |
4 | 14785 | 1.400 |
Price($) | Vol. | No. |
---|---|---|
1.550 | 157 | 1 |
1.580 | 6715 | 2 |
1.600 | 2319 | 1 |
1.620 | 5327 | 1 |
1.630 | 1270 | 1 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |